Cargando…

The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia

The endocannabinoid system is widespread throughout the central nervous system and its type 1 receptor (CB1) plays a crucial role in preventing the neurotoxicity caused by activation of glutamate N-methyl-D-aspartate receptors (NMDARs). Indeed, it is the activity of NMDARs themselves that provides t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Blázquez, Pilar, Rodríguez-Muñoz, María, Garzón, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877778/
https://www.ncbi.nlm.nih.gov/pubmed/24427139
http://dx.doi.org/10.3389/fphar.2013.00169
_version_ 1782297703645970432
author Sánchez-Blázquez, Pilar
Rodríguez-Muñoz, María
Garzón, Javier
author_facet Sánchez-Blázquez, Pilar
Rodríguez-Muñoz, María
Garzón, Javier
author_sort Sánchez-Blázquez, Pilar
collection PubMed
description The endocannabinoid system is widespread throughout the central nervous system and its type 1 receptor (CB1) plays a crucial role in preventing the neurotoxicity caused by activation of glutamate N-methyl-D-aspartate receptors (NMDARs). Indeed, it is the activity of NMDARs themselves that provides the demands on the endogenous cannabinoids in order to control their calcium currents. Therefore, a physiological role of this system is to maintain NMDAR activity within safe limits, thereby protecting neural cells from excitotoxicity. Thus, cannabinoids may be able to control NMDAR overactivation-related neural dysfunctions; however, the major obstacles to the therapeutic utilization of these compounds are their psychotropic effects and negative influence on cognitive performance. Studies in humans have indicated that abuse of smoked cannabis can promote psychosis and even circumstantially precipitate symptoms of schizophrenia, although the latter appears to require a prior vulnerability in the individual. It is possible that cannabinoids provoke psychosis/schizophrenia reflecting a mechanism common to neuroprotection: the reduction of NMDAR activity. Cannabinoids are proposed to produce such effect by reducing the pre-synaptic release of glutamate or interfering with post-synaptic NMDAR-regulated signaling pathways. The efficacy of such control requires the endocannabinoid system to apply its negative influence in a manner that is proportional to the strength of NMDAR signaling. Thus, cannabinoids acting at the wrong time or exerting an inappropriate influence on their receptors may cause NMDAR hypofunction. The purpose of the present review is to draw the attention of the reader to the newly described functional and physical CB1–NMDAR association, which may elucidate the scenario required for the rapid and efficacious control of NMDAR activity. Whether alterations in these mechanisms may increase NMDAR hypofunction leading to vulnerability to schizophrenia will be outlined.
format Online
Article
Text
id pubmed-3877778
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-38777782014-01-14 The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia Sánchez-Blázquez, Pilar Rodríguez-Muñoz, María Garzón, Javier Front Pharmacol Pharmacology The endocannabinoid system is widespread throughout the central nervous system and its type 1 receptor (CB1) plays a crucial role in preventing the neurotoxicity caused by activation of glutamate N-methyl-D-aspartate receptors (NMDARs). Indeed, it is the activity of NMDARs themselves that provides the demands on the endogenous cannabinoids in order to control their calcium currents. Therefore, a physiological role of this system is to maintain NMDAR activity within safe limits, thereby protecting neural cells from excitotoxicity. Thus, cannabinoids may be able to control NMDAR overactivation-related neural dysfunctions; however, the major obstacles to the therapeutic utilization of these compounds are their psychotropic effects and negative influence on cognitive performance. Studies in humans have indicated that abuse of smoked cannabis can promote psychosis and even circumstantially precipitate symptoms of schizophrenia, although the latter appears to require a prior vulnerability in the individual. It is possible that cannabinoids provoke psychosis/schizophrenia reflecting a mechanism common to neuroprotection: the reduction of NMDAR activity. Cannabinoids are proposed to produce such effect by reducing the pre-synaptic release of glutamate or interfering with post-synaptic NMDAR-regulated signaling pathways. The efficacy of such control requires the endocannabinoid system to apply its negative influence in a manner that is proportional to the strength of NMDAR signaling. Thus, cannabinoids acting at the wrong time or exerting an inappropriate influence on their receptors may cause NMDAR hypofunction. The purpose of the present review is to draw the attention of the reader to the newly described functional and physical CB1–NMDAR association, which may elucidate the scenario required for the rapid and efficacious control of NMDAR activity. Whether alterations in these mechanisms may increase NMDAR hypofunction leading to vulnerability to schizophrenia will be outlined. Frontiers Media S.A. 2014-01-02 /pmc/articles/PMC3877778/ /pubmed/24427139 http://dx.doi.org/10.3389/fphar.2013.00169 Text en Copyright © 2014 Sánchez-Blázquez, Rodríguez-Muñoz and Garzón. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Sánchez-Blázquez, Pilar
Rodríguez-Muñoz, María
Garzón, Javier
The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia
title The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia
title_full The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia
title_fullStr The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia
title_full_unstemmed The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia
title_short The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia
title_sort cannabinoid receptor 1 associates with nmda receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877778/
https://www.ncbi.nlm.nih.gov/pubmed/24427139
http://dx.doi.org/10.3389/fphar.2013.00169
work_keys_str_mv AT sanchezblazquezpilar thecannabinoidreceptor1associateswithnmdareceptorstoproduceglutamatergichypofunctionimplicationsinpsychosisandschizophrenia
AT rodriguezmunozmaria thecannabinoidreceptor1associateswithnmdareceptorstoproduceglutamatergichypofunctionimplicationsinpsychosisandschizophrenia
AT garzonjavier thecannabinoidreceptor1associateswithnmdareceptorstoproduceglutamatergichypofunctionimplicationsinpsychosisandschizophrenia
AT sanchezblazquezpilar cannabinoidreceptor1associateswithnmdareceptorstoproduceglutamatergichypofunctionimplicationsinpsychosisandschizophrenia
AT rodriguezmunozmaria cannabinoidreceptor1associateswithnmdareceptorstoproduceglutamatergichypofunctionimplicationsinpsychosisandschizophrenia
AT garzonjavier cannabinoidreceptor1associateswithnmdareceptorstoproduceglutamatergichypofunctionimplicationsinpsychosisandschizophrenia